levofloxacin has been researched along with Cystic Fibrosis of Pancreas in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (16.67) | 29.6817 |
| 2010's | 21 (58.33) | 24.3611 |
| 2020's | 9 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O | 1 |
| Chang, TH; Chuang, YC; Sheng, WH; Wang, JT | 1 |
| Güler, N; Süleyman, A; Tamay, Z | 1 |
| Bianco, F; Brini, R; Caivano, G; Costa, L; Friend, R; Hahn, M; Murgia, X; Mussche, C; Procaccianti, C; Sadafi, H; Schwarz, C; Schwenck, N | 1 |
| Malnarcic, CM; McCaughan, J; Millar, BC; Moore, JE | 1 |
| Griffith, DC; Sabet, M | 1 |
| Damar-Çelik, D; Nørskov-Lauritsen, N; Özbek-Çelik, B | 1 |
| Eschenhagen, PN; Grehn, C; Holz, F; Schwarz, C; Temming, S | 1 |
| Elborn, JS; Flume, PA; Procaccianti, C; Van Devanter, DR | 1 |
| Akdag Cayli, Y; Balducci, AG; Buttini, F; Montanari, S; Oner, L; Sahin, S; Vural, I | 1 |
| Da Dalt, L; Guarnieri, M; Lucca, F; Muffato, G; Rigoli, R; Ros, M | 1 |
| Aoun, V; Chain, JL; Del'Orto, JC; Derbali, RM; Frei, G; Hildgen, P; Moussa, G; Roullin, VG; Tehrani, SF | 1 |
| Hanssens, L; Sputael, V; Van Schandevyl, G | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C | 1 |
| Fiel, SB | 1 |
| Ampofo, K; Hillyard, B; Sherwin, CM; Spigarelli, MG; Stockmann, C | 1 |
| Aaron, SD; Bell, SC; Conrad, D; Dudley, MN; Fischer, R; Flume, PA; Geller, DE; Kerem, E; Loutit, JS; Morgan, EE; Smyth, AR; Stuart Elborn, J; VanDevanter, DR | 1 |
| Cardoso, O; Gaspar, MC; Murtinho, D; Olivier, JC; Pais, AA; Serra, ME; Sousa, JJ; Tewes, F | 1 |
| Celia, C; Ciavarella, MT; Di Bonaventura, G; Di Marzio, L; Fiscarelli, E; Grande, R; Locatelli, M; Paolino, D; Pompilio, A; Ricciotti, G; Zengin, G | 1 |
| Beaudoin, T; LiPuma, JJ; Tom, SK; Waters, V; Yau, YC | 1 |
| Aaron, SD; Bell, SC; Conrad, D; Dudley, MN; Elborn, JS; Fischer, R; Flume, PA; Geller, DE; Kerem, E; Loutit, JS; Morgan, EE; Smyth, AR; VanDevanter, DR | 1 |
| Cohen, F; Elborn, JS; Flume, PA; Loutit, J; VanDevanter, DR | 1 |
| Abraham, GA; Castro, GR; Duran, N; Islan, GA; Tornello, PC | 1 |
| Crocetta, V; Di Bonaventura, G; Pompilio, A; Verginelli, F | 1 |
| Couderc, L; Lémée, L; Marguet, C; Morisse-Pradier, H | 1 |
| Citron, DM; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O | 1 |
| Dudley, MN; Flume, PA; Geller, DE; Griffith, DC; Loutit, JS; Morgan, E; White, D | 1 |
| Conrad, DJ; Fischer, R; Flume, PA; Geller, DE; Loutit, JS; Staab, D | 1 |
| Baquero, F; Cantón, R; Fernández-Olmos, A; García-Castillo, M; Lamas, A; Maiz, L | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Favari, F; Fontana, R; Golini, G; Marchetti, F | 1 |
| Clarke, L; Elborn, JS; Goldsmith, CE; McCaughan, J; McKnight, AJ; Millar, BC; Moore, JE; Reid, A; Shaw, A | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Allen, SE; Amsden, GW; Pai, MP | 1 |
| Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL | 1 |
| Gillespie, T; Masterton, RG | 1 |
6 review(s) available for levofloxacin and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Management of chronic
Topics: Administration, Inhalation; Cystic Fibrosis; Humans; Levofloxacin; Persistent Infection; Pseudomonas Infections; Quality of Life | 2021 |
Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Clinical Trials as Topic; Cystic Fibrosis; Dose-Response Relationship, Drug; Dysgeusia; Humans; Levofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Aerosolized antibiotics in cystic fibrosis: an update.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; Equipment Design; Humans; Levofloxacin; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2014 |
Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Chronic Disease; Cystic Fibrosis; Humans; Levofloxacin; Lung; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum; Time Factors; Treatment Outcome | 2015 |
[Infections in cystic fibrosis: Up-to-date].
Topics: Child; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Early Diagnosis; Early Medical Intervention; Guideline Adherence; Humans; Infant; Levofloxacin; Mycoses; Opportunistic Infections; Respiratory Tract Infections; Treatment Outcome | 2016 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Drug Administration Schedule; Humans; Injections, Intravenous; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
7 trial(s) available for levofloxacin and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Tobramycin; Treatment Outcome; Young Adult | 2015 |
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Double-Blind Method; Drug Monitoring; Female; Forced Expiratory Volume; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Symptom Assessment; Symptom Flare Up; Treatment Outcome | 2016 |
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
Topics: Administration, Inhalation; Adult; Aerosols; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2016 |
Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Single-Blind Method; Solutions | 2011 |
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Solutions; Sputum; Treatment Outcome | 2011 |
Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Biological Availability; Calcium Carbonate; Cations; Cross-Over Studies; Cystic Fibrosis; Drug Administration Schedule; Drug Interactions; Female; Gastrointestinal Transit; Humans; Levofloxacin; Male; Ofloxacin; Osteoporosis; Therapeutic Equivalency | 2006 |
Levofloxacin pharmacokinetics in adult cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Kidney Function Tests; Levofloxacin; Male; Metabolic Clearance Rate; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum | 2007 |
23 other study(ies) available for levofloxacin and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Cystic Fibrosis; Humans; Levofloxacin; Lung Diseases; Microbial Sensitivity Tests; Ofloxacin; Sputum | 2010 |
Clinical characteristics and outcomes of non-cystic fibrosis patients with Burkholderia cepacia complex bacteremia at a medical center in Taiwan.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Burkholderia cepacia; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Fibrosis; Hospitals; Humans; Levofloxacin; Retrospective Studies; Taiwan; Trimethoprim | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis.
Topics: Administration, Inhalation; Adult; Cystic Fibrosis; Humans; Levofloxacin; Lung; Nebulizers and Vaporizers; Respiratory Aerosols and Droplets | 2022 |
Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Topics: Anti-Bacterial Agents; Awareness; Ciprofloxacin; Cystic Fibrosis; Health Occupations; Humans; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Activity of Aerosolized Levofloxacin against Burkholderia cepacia in a Mouse Model of Chronic Lung Infection.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Chronic Disease; Cystic Fibrosis; Female; Humans; Levofloxacin; Lung; Mice; Mice, Inbred BALB C; Respiratory Tract Infections | 2020 |
Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis.
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Chloramphenicol; Colistin; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Meropenem | 2020 |
Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Bacterial Agents; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Levofloxacin; Male; Middle Aged | 2021 |
Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.
Topics: Administration, Inhalation; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Deoxyribonuclease I; Dry Powder Inhalers; Expectorants; Humans; Levofloxacin; Microscopy, Electron, Scanning; Particle Size; Powders; Recombinant Proteins; Spectroscopy, Fourier Transform Infrared | 2017 |
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2018 |
Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study.
Topics: A549 Cells; Anti-Bacterial Agents; Cell Survival; Cystic Fibrosis; Delayed-Action Preparations; Drug Compounding; Drug Evaluation, Preclinical; Drug Liberation; Drug Stability; Humans; Levofloxacin; Liposomes; Microbial Sensitivity Tests; Mucus; Nanoparticles; Pseudomonas aeruginosa; Pseudomonas Infections | 2019 |
A case report of successful eradication of new isolates of
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Burkholderia cenocepacia; Burkholderia Infections; Child, Preschool; Cystic Fibrosis; Humans; Levofloxacin; Male; Maxillary Sinus; Maxillary Sinusitis; Meropenem; Nasal Lavage; Otorhinolaryngologic Surgical Procedures; Penicillins; Trimethoprim, Sulfamethoxazole Drug Combination | 2020 |
Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy.
Topics: Anti-Bacterial Agents; Chitosan; Cross-Linking Reagents; Cystic Fibrosis; Drug Carriers; Drug Liberation; Humans; Levofloxacin; Microspheres; Particle Size; Powder Diffraction; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Therapy; Spectroscopy, Fourier Transform Infrared; Surface Properties; Technology, Pharmaceutical | 2015 |
Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic Fibrosis; Humans; Levofloxacin; Limit of Detection; Solid Phase Microextraction; Sputum | 2015 |
Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.
Topics: Achromobacter; Amikacin; Anti-Bacterial Agents; Aztreonam; Biofilms; Colistin; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Plankton; Tobramycin | 2016 |
Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization.
Topics: Anti-Bacterial Agents; Biofilms; Calorimetry, Differential Scanning; Cystic Fibrosis; Deoxyribonucleases; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Levofloxacin; Lipids; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Pseudomonas aeruginosa; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |
In vitro activity of levofloxacin against planktonic and biofilm Stenotrophomonas maltophilia lifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression.
Topics: Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Genes, MDR; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Pneumonia, Bacterial; Stenotrophomonas maltophilia | 2016 |
Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Aerobiosis; Aerosols; Anaerobiosis; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Ofloxacin; Oxygen; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2010 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; Lung Diseases; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Burkholderia cepacia; Cystic Fibrosis; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Staphylococcus aureus | 2004 |
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Selection, Genetic; Time Factors | 2002 |